Pfizer Licensing Deal with WARF Allows Firm to Develop hESC-based Therapies, Discovery Tools | GenomeWeb

This article was originally published on May 12.

Pfizer and the Wisconsin Alumni Research Foundation said last week that they have inked a licensing agreement that gives Pfizer the right to work with human embryonic stem cells for drug research and discovery.

With the deal, WARF has now inked 35 licensing deals with 27 corporate partners for its portfolio of patents related to isolating and differentiating hESCs in the late 1990s, Janet Kelly, WARF's director communications, wrote in an e-mail to BTW.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.